Table 2.

Clinical, immunological and treatment-related characteristics of adults receiving ART following ‘Test and Treat strategy” in Bahir dar city, Northwest Ethiopia, November 2016 to December 2021.

Variables (N= 1020)	Categories	Failure status		Frequency	%
		Event	Censored
Time to ART initiation	Within 7 days	203	373	576	56.5
	After 7 day	97	347	444	43.5
baseline WHO clinical stage	Stage I and II	178	491	669	65.5
	Stage III and IV	122	229	351	34.5
baseline CD4 category	Greater than 500	62	157	219	21.3
	From 200 to 499	109	304	413	40.5
	<200	129	259	398	38.2
Baseline BMI category	Underweight	95	181	276	27.1
	Normal and/or overweight	205	539	744	72.9
Functional status	Working	224	570	794	77.8
	Ambulatory	58	120	178	17.5
	Bedridden	18	30	48	4.7
History of TB/HIV co-infection	Yes	68	143	215	21.1
	No	232	577	805	78.9
History of OIs	Yes	120	243	363	35.5
	No	180	477	657	64.5
Baseline ART regimen	1e (TDF_3TC_EFV)	234	486	723	70.9
	1j (TDF_3TC- DTG)	29	167	193	18.9
	Others	37	67	104	10.2
History of treatment failure	Yes	17	39	56	5.5
	No	283	681	964	94.5
History of regimen change	Yes	75	190	265	26
	No	225	530	755	74
History of side effects	Yes	49	39	88	8.6
	No	251	681	932	91.4
CPT prophylaxis status	Received	152	378	530	52
	Not-received	148	342	490	48
IPT prophylaxis status	Received	157	440	597	58.5
	Not_ received	143	280	423	41.5

Others:- include 1c(AZT-3TC-NVP), 1d(AZT-3TC-EFV), 1f(TDF-3TC-NVP).

ART - Anti-retroviral Therapy, CD4⁺ cells - Cluster of differentiation cells, CPT-Cotrimoxsazole preventive therapy, IPT- Isoniazid preventive therapy, OIs-opportunistic infections, TB - tuberculosis.